Author's response to reviews

Title: High titer West Nile IVIG from selected donors for treatment of West Nile infection

Authors:

David Ben-Nathan (davidbn@013.net.il)
Orly Gershoni-Yahalom (orlyge@bgu.ac.il)
Itzchak Samina (saminai@moag.gov.il)
Yevgeny Khinich (vaccine@moag.gov.il)
Israel Nur (israel@omrix.co.il)
Orgad Laub (orgad@omrix.co.il)
Ahuva Gottreich (ahuva@sheba.health.gov.il)
Michael Simanov (vaccine@moag.gov.il)
Angel Porgador (angel@bgu.ac.il)
Bracha Rager-Zisman (rager@netvision.net.il)
Nadav Or (nadav@omrix.co.il)

Version: 2 Date: 27 August 2008

Author's response to reviews:

Editor BioMed Central
BMC Infectious Diseases

Dear Editor,

Enclosed please find our manuscript entitled: "High titer West Nile IVIG from selected donors for treatment of West Nile virus infection ", by David Ben Nathan1, Orly Gershoni–Yahalom1, Itzchak Samina3, Yevgeny Khinich3, Israel Nur2, Orgad Laub2, Ahuva Gottreich4, Michael Simanov3 Angel Porgador1, Bracha Rager-Zisman1 and Nadav Orr2

This paper contains novel information on the therapeutic efficacy of WNIG against WNV infection. Positive units were processed into a pharmaceutical grade WNV IVIG (WNIG). The potency of WNIG for neutralization of WNV NY99 strain was tested in vitro by cell neutralizing assay and in vivo by using a mouse lethal model. WNIG was approx 5-10-fold more potent compared to regular IVIG.

We conclude that blood from selected donors in WNV endemic regions improve the potency of IVIG and should be developed for use for therapy and prophylactic measures.

We hope you will find this paper suitable for publication in the journal
BMC Infectious Diseases